Open Access
Open access
Journal of Clinical Investigation, volume 126, issue 9, pages 3377-3382

Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease

Boyraz Baris 1, 2
Moon Diane H. 3
Segal Matthew 3
Muosieyiri Maud Z. 3
Aykanat Asli 3
Tai Albert 4
Cahan Patrick
Agarwal Suneet 3
2
 
HARVARD UNIVERSITY
3
 
Harvard University ,
4
 
TUFTS UNIVERSITY
Publication typeJournal Article
Publication date2016-08-01
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor15.9
ISSN00219738, 15588238
PubMed ID:  27482890
General Medicine
Abstract
The telomerase RNA component (TERC) is a critical determinant of cellular self-renewal. Poly(A)-specific ribonuclease (PARN) is required for posttranscriptional maturation of TERC. PARN mutations lead to incomplete 3' end processing and increased destruction of nascent TERC RNA transcripts, resulting in telomerase deficiency and telomere diseases. Here, we determined that overexpression of TERC increased telomere length in PARN-deficient cells and hypothesized that decreasing posttranscriptional 3' oligo-adenylation of TERC would counteract the deleterious effects of PARN mutations. Inhibition of the noncanonical poly(A) polymerase PAP-associated domain-containing 5 (PAPD5) increased TERC levels in PARN-mutant patient cells. PAPD5 inhibition was also associated with increases in TERC stability, telomerase activity, and telomere elongation. Our results demonstrate that manipulating posttranscriptional regulatory pathways may be a potential strategy to reverse the molecular hallmarks of telomere disease.

Citations by journals

1
2
3
Cell Reports
Cell Reports, 3, 6.67%
Cell Reports
3 publications, 6.67%
Nature Communications
Nature Communications, 2, 4.44%
Nature Communications
2 publications, 4.44%
npj Genomic Medicine
npj Genomic Medicine, 2, 4.44%
npj Genomic Medicine
2 publications, 4.44%
Molecular Cell
Molecular Cell, 2, 4.44%
Molecular Cell
2 publications, 4.44%
Scientific Reports
Scientific Reports, 1, 2.22%
Scientific Reports
1 publication, 2.22%
Current Opinion in Pulmonary Medicine
Current Opinion in Pulmonary Medicine, 1, 2.22%
Current Opinion in Pulmonary Medicine
1 publication, 2.22%
American Journal of Respiratory and Critical Care Medicine
American Journal of Respiratory and Critical Care Medicine, 1, 2.22%
American Journal of Respiratory and Critical Care Medicine
1 publication, 2.22%
Current Topics in Medicinal Chemistry
Current Topics in Medicinal Chemistry, 1, 2.22%
Current Topics in Medicinal Chemistry
1 publication, 2.22%
Cancers
Cancers, 1, 2.22%
Cancers
1 publication, 2.22%
Frontiers in Genetics
Frontiers in Genetics, 1, 2.22%
Frontiers in Genetics
1 publication, 2.22%
Cellular and Molecular Life Sciences
Cellular and Molecular Life Sciences, 1, 2.22%
Cellular and Molecular Life Sciences
1 publication, 2.22%
Nature Reviews Genetics
Nature Reviews Genetics, 1, 2.22%
Nature Reviews Genetics
1 publication, 2.22%
Nature Reviews Molecular Cell Biology
Nature Reviews Molecular Cell Biology, 1, 2.22%
Nature Reviews Molecular Cell Biology
1 publication, 2.22%
Nature Structural and Molecular Biology
Nature Structural and Molecular Biology, 1, 2.22%
Nature Structural and Molecular Biology
1 publication, 2.22%
Seminars in Hematology
Seminars in Hematology, 1, 2.22%
Seminars in Hematology
1 publication, 2.22%
Trends in Molecular Medicine
Trends in Molecular Medicine, 1, 2.22%
Trends in Molecular Medicine
1 publication, 2.22%
Blood advances
Blood advances, 1, 2.22%
Blood advances
1 publication, 2.22%
American Journal of Human Genetics
American Journal of Human Genetics, 1, 2.22%
American Journal of Human Genetics
1 publication, 2.22%
Cell Stem Cell
Cell Stem Cell, 1, 2.22%
Cell Stem Cell
1 publication, 2.22%
Trends in Pharmacological Sciences
Trends in Pharmacological Sciences, 1, 2.22%
Trends in Pharmacological Sciences
1 publication, 2.22%
Journal of Biological Chemistry
Journal of Biological Chemistry, 1, 2.22%
Journal of Biological Chemistry
1 publication, 2.22%
Antiviral Research
Antiviral Research, 1, 2.22%
Antiviral Research
1 publication, 2.22%
Best Practice and Research in Clinical Haematology
Best Practice and Research in Clinical Haematology, 1, 2.22%
Best Practice and Research in Clinical Haematology
1 publication, 2.22%
iScience
iScience, 1, 2.22%
iScience
1 publication, 2.22%
Life Sciences
Life Sciences, 1, 2.22%
Life Sciences
1 publication, 2.22%
Advances in Biological Regulation
Advances in Biological Regulation, 1, 2.22%
Advances in Biological Regulation
1 publication, 2.22%
Wiley interdisciplinary reviews. RNA
Wiley interdisciplinary reviews. RNA, 1, 2.22%
Wiley interdisciplinary reviews. RNA
1 publication, 2.22%
FEBS Letters
FEBS Letters, 1, 2.22%
FEBS Letters
1 publication, 2.22%
Cell Cycle
Cell Cycle, 1, 2.22%
Cell Cycle
1 publication, 2.22%
1
2
3

Citations by publishers

2
4
6
8
10
12
14
16
Elsevier
Elsevier, 15, 33.33%
Elsevier
15 publications, 33.33%
Springer Nature
Springer Nature, 9, 20%
Springer Nature
9 publications, 20%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 2, 4.44%
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 4.44%
American Society of Hematology
American Society of Hematology, 2, 4.44%
American Society of Hematology
2 publications, 4.44%
Wiley
Wiley, 2, 4.44%
Wiley
2 publications, 4.44%
Taylor & Francis
Taylor & Francis, 2, 4.44%
Taylor & Francis
2 publications, 4.44%
Oxford University Press
Oxford University Press, 2, 4.44%
Oxford University Press
2 publications, 4.44%
American Association for the Advancement of Science (AAAS)
American Association for the Advancement of Science (AAAS), 2, 4.44%
American Association for the Advancement of Science (AAAS)
2 publications, 4.44%
Wolters Kluwer Health
Wolters Kluwer Health, 1, 2.22%
Wolters Kluwer Health
1 publication, 2.22%
American Thoracic Society
American Thoracic Society, 1, 2.22%
American Thoracic Society
1 publication, 2.22%
Bentham Science
Bentham Science, 1, 2.22%
Bentham Science
1 publication, 2.22%
Frontiers Media S.A.
Frontiers Media S.A., 1, 2.22%
Frontiers Media S.A.
1 publication, 2.22%
American Society for Biochemistry and Molecular Biology
American Society for Biochemistry and Molecular Biology, 1, 2.22%
American Society for Biochemistry and Molecular Biology
1 publication, 2.22%
Portland Press
Portland Press, 1, 2.22%
Portland Press
1 publication, 2.22%
2
4
6
8
10
12
14
16
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Boyraz B. et al. Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease // Journal of Clinical Investigation. 2016. Vol. 126. No. 9. pp. 3377-3382.
GOST all authors (up to 50) Copy
Boyraz B., Moon D. H., Segal M., Muosieyiri M. Z., Aykanat A., Tai A., Cahan P., Agarwal S. Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease // Journal of Clinical Investigation. 2016. Vol. 126. No. 9. pp. 3377-3382.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1172/JCI87547
UR - https://doi.org/10.1172%2FJCI87547
TI - Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease
T2 - Journal of Clinical Investigation
AU - Boyraz, Baris
AU - Moon, Diane H.
AU - Segal, Matthew
AU - Muosieyiri, Maud Z.
AU - Aykanat, Asli
AU - Tai, Albert
AU - Cahan, Patrick
AU - Agarwal, Suneet
PY - 2016
DA - 2016/08/01 00:00:00
PB - American Society for Clinical Investigation
SP - 3377-3382
IS - 9
VL - 126
PMID - 27482890
SN - 0021-9738
SN - 1558-8238
ER -
BibTex |
Cite this
BibTex Copy
@article{2016_Boyraz,
author = {Baris Boyraz and Diane H. Moon and Matthew Segal and Maud Z. Muosieyiri and Asli Aykanat and Albert Tai and Patrick Cahan and Suneet Agarwal},
title = {Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease},
journal = {Journal of Clinical Investigation},
year = {2016},
volume = {126},
publisher = {American Society for Clinical Investigation},
month = {aug},
url = {https://doi.org/10.1172%2FJCI87547},
number = {9},
pages = {3377--3382},
doi = {10.1172/JCI87547}
}
MLA
Cite this
MLA Copy
Boyraz, Baris, et al. “Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease.” Journal of Clinical Investigation, vol. 126, no. 9, Aug. 2016, pp. 3377-3382. https://doi.org/10.1172%2FJCI87547.
Found error?